Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has relaunched its product sales in Ireland under the Medical Cannabis Access Program (MCAP). The company continues to expand its presence in Europe.
This Tuesday, it announced its product will be easily accessible and covered for patients eligible. Patients will first get access to the oral solution but more Tilray products will be available once regulations allow.
However, possessing cannabis is illegal in Ireland unless people have a Ministerial Licence. Medical cannabis use is highly regulated and approved only for some medical conditions. In December 2016, the ministry issued the first licence to a two-year-old child with Dravet Syndrome.
“We are extremely proud to relaunch in Ireland with an expanded footprint,” head of international business Denise Faltischek said.
“The MCAP reimbursement approval is a tremendous step in providing patients with greater access to Tilray’s high-quality medical cannabis products that address their needs. We remain dedicated to do our part to increase access for patients in need around the world.”
Tilray sells THC and CBD products in 20 countries. Tilray was the first licensed producer of medical pot in Canada and sells brands including Aphria, Broken Coast, and Symbios.
Company stock went up by 2.3 per cent on Tuesday to $4.02 on the Toronto Securities Exchange.
Read more: Tilray receives approval to distribute cannabis oral solution in Italy
